InvestorsHub Logo
Followers 87
Posts 6692
Boards Moderated 1
Alias Born 09/18/2009

Re: None

Tuesday, 10/03/2023 5:37:47 PM

Tuesday, October 03, 2023 5:37:47 PM

Post# of 42925
Congratulations to Novavax on the FDA authorization of their vaccine for the 2023-2024 treatment year.

https://www.yahoo.com/news/fda-signs-off-novavax-covid-184916733.html

It seems the processing of their saponin adjuvant may be responsive to lenz, if not just replaced by lenz.

https://www.novavax.com/science-technology/matrix-m-adjuvant-technology

I hope this opens the door to lenz to be used in the US as part of our patented lenz/vaccine/anti-viral cocktail, which could prove to be the world's first covid vaccine, in the true sense of the word.

"METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY
Publication number: 20230109208
Abstract: The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.
Type: Application
Filed: March 8, 2021
Publication date: April 6, 2023
Applicant: HUMANIGEN, INC.
Inventors: Cameron DURRANT, Dale CHAPPEL"

https://patents.justia.com/assignee/humanigen-inc

It would be a major expansion of lenzilumab's market opportunity, to be used not only as a treatment, but as a preventative, as well. In fact, after the initial traditional lenz/vaccine/anti-viral treatment, or the initial infection, lenz may be the only drug needed to prevent and/or to treat future covid pneumonia infections.